Cytomegalovirus (CMV) DNA Quantitation in Bronchoalveolar Lavage Fluid from Hematopoietic Stem Cell Transplant Recipients with CMV Pneumonia

Journal of Infectious Diseases

Volumn 215, Issue 10, 2017, Pages 1514-1522

  Boeckh, Michael ^a,b   Stevens Ayers, Terry ^a   Travi, Giovanna ^a   Huang, Meei Li ^a,d   Cheng, Guang Shing ^a,b   Xie, Hu ^a   Leisenring, Wendy ^a,c   Erard, Veronique ^a   Seo, Sachiko ^a   Kimball, Louise ^a   Corey, Lawrence ^a,b,d   Pergam, Steven A ^a,b   Jerome, Keith R ^a,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Department of Medicine ^*  (United States)

^c Division of Biostatistics   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

cytomegalovirus; pneumonia.; viral load

Indexed keywords

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS PNEUMONIA; FEMALE; GRAFT RECIPIENT; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; VIRUS LOAD; VIRUS PNEUMONIA; VIRUS SHEDDING; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; PROCEDURES; STATISTICS AND NUMERICAL DATA; VIROLOGY;

VIRUS DNA;

ADULT; BRONCHOALVEOLAR LAVAGE FLUID; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, VIRAL; ROC CURVE; VIRAL LOAD;

EID: 85020208570     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix048     Document Type: Article

References (37)

1. Erard V, Guthrie KA, Seo S, et al. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis 2015; 61:31-9.
2. Chemaly RF, Ullmann AJ, Stoelben S, et al.; AIC246 Study Team. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014; 370:1781-9.
3. Marty FM, Winston DJ, Rowley SD, et al.; CMX001-201 Clinical Study Group. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369:1227-36.
4. Crawford SW, Bowden RA, Hackman RC, Gleaves CA, Meyers JD, Clark JG. Rapid detection of cytomegalovirus pulmonary infection by bronchoalveolar lavage and centrifugation culture. Ann Intern Med 1988; 108:180-5.
5. Burgener EB, Waggoner J, Pinsky BA, Chen SF. Clinical characteristics and outcomes of pediatric patients with CMV DNA detection in bronchoalveolar lavage fluid. Ped Pulmonol 2017; 52:112-8.
6. Coussement J, Steensels D, Nollevaux MC, et al. When polymerase chain reaction does not help: cytomegalovirus pneumonitis associated with very low or undetectable viral load in both blood and bronchoalveolar lavage samples after lung transplantation. Transpl Infect Dis 2016; 18:284-7.
7. Rozy A, Duk K, Szumna B, Skronska P, Gawryluk D, Chorostowska-Wynimko J. Effectiveness of PCR and immunofluorescence techniques for detecting human cytomegalovirus in blood and bronchoalveolar lavage fluid. Adv Exp Med Biol 2016; 921:21-6.
8. Tan SK, Burgener EB, Waggoner JJ, et al. Molecular and culture-based bronchoalveolar lavage fluid testing for the diagnosis of cytomegalovirus pneumonitis. Open Forum Infect Dis 2016; 3:ofv212.
9. Ljungman P, Griffiths P, Paya C. Definitions of Cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34:1094-7.
10. Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of CMV infection and disease in transplant patients for use in clinical trials. Clin Infect Dis 2017; 64:87-91.
11. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The city of hope-stanford-syntex CMV study group. N Engl J Med 1991; 324:1005-11.
12. Slavin MA, Gooley TA, Bowden RA. Prediction of cytomegalovirus pneumonia after marrow transplantation from cellular characteristics and cytomegalovirus culture of bronchoalveolar lavage fluid. Transplantation 1994; 58:915-9.
13. Crawford SW, Hackman RC, Clark JG. Open lung biopsy diagnosis of diffuse pulmonary infiltrates after marrow transplantation. Chest 1988; 94:949-53.
14. Bissinger AL, Einsele H, Hamprecht K, et al. Infectious pulmonary complications after stem cell transplantation or chemotherapy: diagnostic yield of bronchoalveolar lavage. Diagn Microbiol Infect Dis 2005; 52:275-80.
15. Gerna G, Vitulo P, Rovida F, et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol 2006; 78:408-16.
16. Cathomas G, Morris P, Pekle K, Cunningham I, Emanuel D. Rapid diagnosis of cytomegalovirus pneumonia in marrow transplant recipients by bronchoalveolarlavage using the polymerase chain reaction, virus culture, and the direct immunostaining of alveolar cells. Blood 1993; 81:1909-14.
17. Boivin G, Olson CA, Quirk MR, Kringstad B, Hertz MI, Jordan MC. Quantitation of cytomegalovirus DNA and characterization of viral gene expression in bronchoalveolar cells of infected patients with and without pneumonitis. J Infect Dis 1996; 173:1304-12.
18. Seo S, Renaud C, Kuypers JM, et al. Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies. Blood 2015; 125:3789-97.
19. Nakamae H, Kirby KA, Sandmaier BM, et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15:694-703.
20. Pergam SA, Xie H, Sandhu R, et al. Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients. Biol Blood Marrow Transplant 2012; 18:1391-400.
21. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325:1601-7.
22. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 1996; 88:4063-71.
23. Green ML, Leisenring W, Stachel D, et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18:1391-1400.
24. Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007; 110:3071-7.
25. Alexander BT, Hladnik LM, Augustin KM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy 2010; 30:554-61.
26. Haslam PL, Baughman RP. Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. Eur Respir J 1999; 14:245-8.
27. Harris B, Lowy FD, Stover DE, Arcasoy SM. Diagnostic bronchoscopy in solid-organ and hematopoietic stem cell transplantation. Ann Am Thorac Soc 2013; 10:39-49.
28. Campbell AP, Guthrie KA, Englund JA, et al. Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant. Clin Infect Dis 2015; 61:192-202.
29. Boeckh M, Huang M, Ferrenberg J, et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004; 42:1142-8.
30. Frealle E, Decrucq K, Botterel F, et al. Diagnosis of invasive aspergillosis using bronchoalveolar lavage in haematology patients: influence of bronchoalveolar lavage human DNA content on real-time PCR performance. Eur J Clin Microbiol Infect Dis 2009; 28:223-32.
31. Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239:487-91.
32. Cone RW, Hackman RC, Huang ML, et al. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med 1993; 329:156-61.
33. D'Haese J, Theunissen K, Vermeulen E, et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: Analytical and clinical validity. J Clin Microbiol 2012; 50:1258-63.
34. Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: A review of ten years' experience. Rev Infect Dis 1982; 4:1119-32.
35. Campbell AP, Chien JW, Kuypers J, et al. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): Associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. J Infect Dis 2010; 201:1404-13.
36. Renaud C, Xie H, Seo S, et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant 2013; 19:1220-6.
37. Seo S, Xie H, Campbell AP, et al. Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome. Clin Infect Dis 2014; 58:1357-68.